

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

NCT06839469

Status RECRUITING
Sponsor Columbia University
Enrollment 106 participants

Key Eligibility Criteria

Inclusion (4)

- Genetic confirmation of disease (DMD, SMA) or healthy control
- Able to walk independently at least 25 meters
- Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD
- Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.

Exclusion (3)

- Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation
- Use investigational medications intended for treatment of NMD within 30 days
- Prior to study entry had an injury or surgery that would impact gait within the previous 3 months

Locations (3 total)

Stanford University, Palo Alto, California, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Columbia University Irving Medical Center, New York, New York, United States